GenSight Biologics Company
We are an innovative clinical-stage gene therapy company currently focused on discovering, developing and commercializing novel therapies for patients with severe retinal neurodegenerative diseases. In the longer term, we hope to find solutions for patients faced with neurodegenerative diseases more generally.
Investors
.jpg)
Technology:
Neurological Disorders
Estimated Revenue:
$1M to $10M
Founded Date:
2012
Headquarters:
France
Funding Status:
IPO
Industry:
Energetic Process